- Home
- ACVA vs EVMN Comparison
ACVA vs EVMN Comparison
Compare ACVA & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACVA | EVMN |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.4M | 892.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACVA | EVMN |
|---|---|---|
| Price | $5.03 | $27.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $11.32 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 2.3M | 265.1K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $759,606,000.00 | N/A |
| Revenue This Year | $14.01 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.22 | N/A |
| 52 Week Low | $4.07 | $13.89 |
| 52 Week High | $17.16 | $33.20 |
Technical Indicators
Market Signals| Indicator | ACVA | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 57.92 |
| Support Level | $4.95 | $21.14 |
| Resistance Level | $5.67 | $28.82 |
| Average True Range (ATR) | 0.27 | 1.90 |
| MACD | 0.13 | 0.32 |
| Stochastic Oscillator | 87.56 | 79.51 |
Price Performance
Historical ComparisonAbout ACVA ACV Auctions Inc.
ACV Auctions Inc operates a mobile platform for wholesale car auctions. It provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers. Additionally, the company's marketplace platform is supported by remarketing centers in various locations throughout the United States.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.